Safety and Efficacy of Convalescent Plasma to Treat Severe COVID-19: Protocol for the Saudi Collaborative Multicenter Phase II Study

BACKGROUND: The COVID-19 pandemic is expected to cause significant morbidity and mortality. The development of an effective vaccine will take several months to become available, and its affordability is unpredictable. Transfusion of convalescent plasma (CP) may provide passive immunity. Based on ini...

Descripción completa

Detalles Bibliográficos
Autores principales: Albalawi, Mohammed, Zaidi, Syed Ziauddin Ahmed, AlShehry, Nawal, AlAskar, Ahmed, Zaidi, Abdul Rehman Zia, Abdallah, Rania Nagib Mohammed, Salam, Abdul, AlSagheir, Ahmed, AlMozain, Nour, Elgohary, Ghada, Batarfi, Khalid, Alfaraedi, Alia, Khojah, Osamah, Al-Ansari, Rehab, Alfaraj, Mona, Dayel, Afra, Al Bahrani, Ahmed, Abdelhameed, Arwa Nabhan, Alhumaidan, Hind, Al-Otaibi, Jawaher M, Radwi, Ghazala, Raizah, Abdulrahman, Shatry, Hind, Alsaleh, Sara, AlZahrani, Hazzaa, Al-Hashmi, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2020
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546730/
https://www.ncbi.nlm.nih.gov/pubmed/32903199
http://dx.doi.org/10.2196/23543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546730/
https://www.ncbi.nlm.nih.gov/pubmed/32903199
http://dx.doi.org/10.2196/23543

Ejemplares similares